Annovis Bio (ANVS) AI Stock Analysis

• Market Cap: $68.38M
• Dividend Yield: N/A
• Average Volume (3M): 432.13K
• Price to Earnings (P/E): ―
• Beta (1Y): 3.27
• Revenue Growth: N/A
• EPS Growth: 62.84%
• Country: US
• Employees: 8
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.37
• Shares Outstanding: 26,502,890
• 10 Day Avg. Volume: 436,222
• 30 Day Avg. Volume: 432,133
• PEG Ratio: >-0.01
• Price to Book (P/B): 6.58
• Price to Sales (P/S): 0.00
• P/FCF Ratio: >-0.01
• Enterprise Value/Market Cap: 0.48
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: -1.22
• 1Y Price Target: $12.50
• Price Target Upside: 384.50% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2
• EPS Forecast (FY): -1.3
• Revenue Forecast (FY): N/A

• Rating: 46 Neutral
• Price Target: $2.50 ▼(-3.10% Downside)

The score is primarily held down by weak financial performance (pre-revenue, ongoing losses and cash burn) and a valuation profile dominated by negative earnings. Technicals are mixed (better longer-term trend but weaker near-term), and the recent $6M equity raise modestly helps funding runway while adding dilution risk.

Positive Factors

Debt-Free Balance Sheet

Zero reported debt reduces refinancing pressure and preserves financial flexibility during long, capital-intensive clinical programs. This structural balance-sheet strength lowers bankruptcy risk and lets management prioritize R&D spending without near-term interest obligations.

Improved Capitalization

Equity moving from negative to positive and rising total assets indicate improved capitalization versus prior years. That reduces short-term solvency risk, extends operational runway, and increases the firm's ability to reach clinical milestones before needing more dilutive financing.

Focused Clinical Program

Concentrating resources on buntanetap for Alzheimer’s and Parkinson’s focuses R&D and management attention on a single high-unmet-need opportunity. A clear, durable clinical focus can accelerate decision points and efficient capital deployment compared with a fragmented pipeline.

Negative Factors

Pre-Revenue with Sustained Losses

Being pre-revenue with roughly -$25M TTM operating/FCF and negative EBIT (~-$26.7M) is a structural constraint. Continued R&D losses require repeated financing, risk equity erosion over time, and create execution pressure to deliver clinical readouts or partnerships that materially change cash needs.

Weak Cash Generation and Data Uncertainty

Consistently negative operating and free cash flow relative to small asset base makes the business dependent on external capital. The anomalous -$21.9B 2024 cash-flow datapoint creates modeling uncertainty, complicating reliable runway forecasts and financing planning for management and investors.

Reliance on Equity Financing / Dilution Risk

The recent equity raise provides near-term funds but highlights structural reliance on capital markets. Recurrent dilutive financings can erode shareholder value and force timing or scope changes in clinical programs if access to favorable funding terms tightens.

Annovis Bio Business Overview & Revenue Model

Company Description

Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead compound is Buntanetap, an orally administered drug, which has completed Phase 2a clinical trials for the treatment of Alzheimer's disease (AD) and Parkinson's disease, as well as is in clinical trials for Alzheimer's disease in Down Syndrome and other chronic neurodegenerative disorders. It is also developing ANVS405 for protecting the traumatic brain injury and stroke; and ANVS301, which is in Phase I clinical trials to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Berwyn, Pennsylvania.

How the Company Makes Money

Annovis Bio generates revenue primarily through the development and potential commercialization of its therapeutic candidates. The company's revenue model is centered around advancing its drug candidates through clinical trials and eventually receiving regulatory approval for commercialization. Once a drug is approved, Annovis Bio may earn money through direct sales, licensing agreements, or partnerships with larger pharmaceutical companies for distribution and marketing. Additionally, the company may also receive funding from grants or collaborative research agreements with other institutions. However, as a clinical-stage company, Annovis Bio may not currently have significant revenue streams from commercialized products.

Annovis Bio Financial Statement Overview

Summary

Financial profile is constrained by being pre-revenue with persistent losses and ongoing cash burn (TTM operating/FCF roughly -$25M). The balance sheet is a relative positive with $0 debt and improved positive equity, but funding dependence remains high; the cash-flow data also includes an outlier figure that adds uncertainty.

Income Statement

The company is still pre-revenue (zero revenue across the provided periods), which keeps profitability metrics structurally weak. Losses remain sizable: EBIT is about -$26.7M in TTM (Trailing-Twelve-Months), similar to 2024, and while net loss improved versus 2023 (from about -$56.2M to roughly -$24.9M in TTM), earnings are still deeply negative and margins are effectively not meaningful given no revenue. Overall, this reads as an R&D-stage biotech with ongoing operating losses and limited visibility into near-term operating leverage.

Balance Sheet

A key positive is the absence of debt (total debt is $0 across periods), which reduces financial risk and refinancing pressure. Equity has recovered from negative in 2023 to positive in 2024 (~$9.3M) and TTM (~$13.2M), and total assets increased to ~$17.2M in TTM from ~$13.9M in 2024—suggesting improved capitalization versus the prior year. The main weakness is that the business is still loss-making, which can erode equity over time if cash burn continues; returns on equity are volatile and distorted by prior equity swings.

Cash Flow

Cash generation is a clear weakness: operating cash flow and free cash flow are both negative in every period provided, including TTM (Trailing-Twelve-Months) at roughly -$25.0M. The cash burn improved versus 2023 (about -$40.0M), but remains meaningful relative to the company’s balance sheet, implying continued reliance on external funding. There is also an extreme 2024 operating cash flow figure in the data (about -$21.9B), which appears inconsistent with the company’s size and assets and introduces data-quality uncertainty; even excluding that, the underlying trend remains sustained negative free cash flow.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00	0.00
Gross Profit	0.00	0.00	0.00	0.00	0.00	0.00
EBITDA	-26.55M	-26.69M	-45.03M	-25.51M	-14.50M	0.00
Net Income	-24.88M	-24.59M	-56.20M	-25.33M	-14.49M	-5.46M
Balance Sheet
Total Assets	17.19M	13.93M	10.21M	36.02M	46.00M	8.12M
Cash, Cash Equivalents and Short-Term Investments	15.29M	10.55M	5.75M	28.38M	45.69M	8.07M
Total Debt	0.00	0.00	0.00	0.00	0.00	0.00
Total Liabilities	4.03M	4.62M	17.96M	7.70M	1.51M	578.38K
Stockholders Equity	13.16M	9.31M	-7.75M	28.32M	44.49M	7.54M
Cash Flow
Free Cash Flow	-24.98M	-21.89B	-39.97M	-17.31M	-9.13M	-3.97M
Operating Cash Flow	-24.98M	-21.89B	-39.97M	-17.31M	-9.13M	-3.97M
Investing Cash Flow	0.00	0.00	0.00	0.00	0.00	0.00
Financing Cash Flow	27.63M	26.69B	17.34M	4.61K	46.74M	12.04M

Annovis Bio Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 2.58
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ANVS, the sentiment is Negative. The current price of 2.58 is below the 20-day moving average (MA) of 2.99, below the 50-day MA of 3.63, and below the 200-day MA of 2.66, indicating a bearish trend. The MACD of -0.26 indicates Positive momentum. The RSI at 31.01 is Neutral, neither overbought nor oversold. The STOCH value of 9.84 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ANVS.

Annovis Bio Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
WHWK	56 Neutral	$136.67M	19.96	-13.82%	―	-42.62%	―
ABOS	54 Neutral	$148.40M	-1.02	-85.93%	―	―	-60.99%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
ANVS	46 Neutral	$68.38M	-1.64	-246.14%	―	―	62.84%
DTIL	46 Neutral	$92.19M	―	-205.16%	―	-99.07%	-10347.56%
COYA	45 Neutral	$99.60M	-4.01	-62.18%	―	-58.26%	-53.20%

Annovis Bio Corporate Events

Annovis Bio Hosts Regulation FD Investor Information Webinar

On January 28, 2026, Annovis Bio, Inc. held a webinar, supported by a prepared presentation that was made available to participants and stakeholders. The event signaled an effort by the company to formally communicate information to the market via a structured public forum, though no additional operational or strategic details were disclosed in the announcement.

The most recent analyst rating on (ANVS) stock is a Hold with a $3.00 price target. To see the full list of analyst forecasts on Annovis Bio stock, see the ANVS Stock Forecast page.